New study on Ozempic: Helps people keep weight off for up to 4 years and reduces heart disease
2024-05-16 13:36:27
TiranaPost
The weight loss drug semaglutide - commonly known as Ozempic and Wegovy - reduced cardiovascular disease despite weight loss, according to a new study.
It also helped people keep their weight down for at least four years.
That's according to two new analyzes of a large trial presented at the European Congress on Obesity in Venice.
Semaglutide is the main active ingredient in the popular weight loss drugs Ozempic and Wegovy. It mimics the hormone GLP-1 which can signal your body that you are full.
The study included more than 17,600 adults from 41 countries between October 2018 and March 2021 with pre-existing cardiovascular disease and who were overweight or obese.
It was funded by Novo Nordisk, the Danish pharmaceutical company behind the drug.
